Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Antitoxin Treatment of Inhalation Anthrax: A Systematic Review.

Huang E, Pillai SK, Bower WA, Hendricks KA, Guarnizo JT, Hoyle JD, Gorman SE, Boyer AE, Quinn CP, Meaney-Delman D.

Health Secur. 2015 Nov-Dec;13(6):365-77. doi: 10.1089/hs.2015.0032. Review.

PMID:
26690378
2.

Efficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthrax.

Biron B, Beck K, Dyer D, Mattix M, Twenhafel N, Nalca A.

Antimicrob Agents Chemother. 2015 Apr;59(4):2206-14. doi: 10.1128/AAC.04593-14. Epub 2015 Feb 2.

3.
4.

Pathology and pathophysiology of inhalational anthrax in a guinea pig model.

Savransky V, Sanford DC, Syar E, Austin JL, Tordoff KP, Anderson MS, Stark GV, Barnewall RE, Briscoe CM, Lemiale-Biérinx L, Park S, Ionin B, Skiadopoulos MH.

Infect Immun. 2013 Apr;81(4):1152-63. doi: 10.1128/IAI.01289-12. Epub 2013 Jan 28.

5.

Anthrax lethal toxin and the induction of CD4 T cell immunity.

Ascough S, Ingram RJ, Altmann DM.

Toxins (Basel). 2012 Oct;4(10):878-99. doi: 10.3390/toxins4100878. Epub 2012 Oct 19. Review.

6.

Identification of novel and cross-species seroreactive proteins from Bacillus anthracis using a ligation-independent cloning-based, SOS-inducible expression system.

McWilliams BD, Palzkill T, Weinstock GM, Petrosino JF.

Microb Pathog. 2012 Nov-Dec;53(5-6):250-8. doi: 10.1016/j.micpath.2012.08.006. Epub 2012 Sep 10.

7.

A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques.

Quinn CP, Sabourin CL, Niemuth NA, Li H, Semenova VA, Rudge TL, Mayfield HJ, Schiffer J, Mittler RS, Ibegbu CC, Wrammert J, Ahmed R, Brys AM, Hunt RE, Levesque D, Estep JE, Barnewall RE, Robinson DM, Plikaytis BD, Marano N; AVRP Laboratory Working Group.

Clin Vaccine Immunol. 2012 Nov;19(11):1730-45. doi: 10.1128/CVI.00324-12. Epub 2012 Aug 29.

8.

Inhalational anthrax (Ames aerosol) in naïve and vaccinated New Zealand rabbits: characterizing the spread of bacteria from lung deposition to bacteremia.

Gutting BW, Nichols TL, Channel SR, Gearhart JM, Andrews GA, Berger AE, Mackie RS, Watson BJ, Taft SC, Overheim KA, Sherwood RL.

Front Cell Infect Microbiol. 2012 Jun 28;2:87. doi: 10.3389/fcimb.2012.00087. eCollection 2012.

9.

Recombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax.

Leffel EK, Bourdage JS, Williamson ED, Duchars M, Fuerst TR, Fusco PC.

Clin Vaccine Immunol. 2012 Aug;19(8):1158-64. doi: 10.1128/CVI.00240-12. Epub 2012 Jun 13.

10.

The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax.

Brenneman KE, Doganay M, Akmal A, Goldman S, Galloway DR, Mateczun AJ, Cross AS, Baillie LW.

FEMS Immunol Med Microbiol. 2011 Jul;62(2):164-72. doi: 10.1111/j.1574-695X.2011.00800.x. Epub 2011 Apr 15.

11.
12.

Analysis of antibody responses to protective antigen-based anthrax vaccines through use of competitive assays.

Brady RA, Verma A, Meade BD, Burns DL.

Clin Vaccine Immunol. 2010 Sep;17(9):1390-7. doi: 10.1128/CVI.00145-10. Epub 2010 Jul 14.

13.
14.

Anthrax LFn-PA Hybrid Antigens: Biochemistry, Immunogenicity, and Protection Against Lethal Ames Spore Challenge in Rabbits.

Li Q, Peachman KK, Sower L, Leppla SH, Shivachandra SB, Matyas GR, Peterson JW, Alving CR, Rao M, Rao VB.

Open Vaccine J. 2009;2:92-99.

15.

Comparison of three anthrax toxin neutralization assays.

Ngundi MM, Meade BD, Lin TL, Tang WJ, Burns DL.

Clin Vaccine Immunol. 2010 Jun;17(6):895-903. doi: 10.1128/CVI.00513-09. Epub 2010 Apr 7.

16.

Killed but metabolically active Bacillus anthracis vaccines induce broad and protective immunity against anthrax.

Skoble J, Beaber JW, Gao Y, Lovchik JA, Sower LE, Liu W, Luckett W, Peterson JW, Calendar R, Portnoy DA, Lyons CR, Dubensky TW Jr.

Infect Immun. 2009 Apr;77(4):1649-63. doi: 10.1128/IAI.00530-08. Epub 2009 Jan 21.

17.

Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax.

Gauthier YP, Tournier JN, Paucod JC, Corre JP, Mock M, Goossens PL, Vidal DR.

Infect Immun. 2009 Mar;77(3):1197-207. doi: 10.1128/IAI.01217-08. Epub 2008 Dec 29.

18.

Mucosal immunization with attenuated Salmonella enterica serovar Typhi expressing protective antigen of anthrax toxin (PA83) primes monkeys for accelerated serum antibody responses to parenteral PA83 vaccine.

Galen JE, Chinchilla M, Pasetti MF, Wang JY, Zhao L, Arciniega-Martinez I, Silverman DJ, Levine MM.

J Infect Dis. 2009 Feb 1;199(3):326-35. doi: 10.1086/596066.

19.

Discriminating virulence mechanisms among Bacillus anthracis strains by using a murine subcutaneous infection model.

Chand HS, Drysdale M, Lovchik J, Koehler TM, Lipscomb MF, Lyons CR.

Infect Immun. 2009 Jan;77(1):429-35. doi: 10.1128/IAI.00647-08. Epub 2008 Nov 3.

20.

Interlaboratory comparison of results of an anthrax lethal toxin neutralization assay for assessment of functional antibodies in multiple species.

Omland KS, Brys A, Lansky D, Clement K, Lynn F; Participating Laboratories.

Clin Vaccine Immunol. 2008 Jun;15(6):946-53. doi: 10.1128/CVI.00003-08. Epub 2008 Apr 16.

Items per page

Supplemental Content

Write to the Help Desk